The Safety and Tolerability of Aripiprazole Once-Monthly as Maintenance Treatment for Bipolar I Disorder: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study

Second-generation atypical antipsychotics (SGAs) have demonstrated efficacy in the treatment of bipolar I disorder (BP-I) (Keck et  al., 2009a; Keck et al., 2009b; Keck et al., 2007; Quiroz et al., 2010; Tohen et al., 2005) and are recommended in the American Psychiatric Association guidelines for the management of BP-I (American Psychiatric Association, 2002). SGA safety and tolerability profiles include a number of com mon adverse effects, including extrapyramidal symptoms (EPS), metabolic-related side effects, weight gain, and hyperprolactinemia (De Hert et al., 2014; De Hert et al., 2012; Gao et al., 2008; Nasrallah, 2008).

Source: Journal of Affective Disorders - July 6, 2018 Category: Neurology Authors: Joseph R. Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Brian Johnson, Pamela P. Perry, Peter Hertel, Pedro Such, Robert D. McQuade, Margaretta Nyilas, William H. Carson Tags: Research paper Source Type: research